AC Immune (NASDAQ:ACIU) Rating Lowered to “Sell” at Wall Street Zen

AC Immune (NASDAQ:ACIU) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities analysts have also recently commented on ACIU. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

AC Immune Stock Down 6.2%

AC Immune stock opened at $3.19 on Friday. The stock has a market cap of $320.31 million, a price-to-earnings ratio of -3.80 and a beta of 1.62. The business has a 50-day simple moving average of $3.21 and a 200 day simple moving average of $2.87. AC Immune has a 52 week low of $1.43 and a 52 week high of $4.00.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%.The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $0.81 million. On average, research analysts anticipate that AC Immune will post -0.62 earnings per share for the current year.

Institutional Trading of AC Immune

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its holdings in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. Sei Investments Co. purchased a new position in AC Immune in the 2nd quarter worth approximately $51,000. Assenagon Asset Management S.A. purchased a new position in AC Immune in the 3rd quarter worth approximately $549,000. Private Advisor Group LLC bought a new stake in AC Immune in the third quarter valued at approximately $48,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune during the third quarter valued at approximately $63,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.